Experimental cell therapy tested for Tough-to-Treat blood disorder
NCT ID NCT07287930
Summary
This early-stage study is testing the safety and initial effectiveness of a new cell therapy called YTS109 for adults with severe autoimmune hemolytic anemia (AIHA) who have not improved after at least three other treatments. The study will enroll about 13 participants to find a safe dose and see how their bodies handle the therapy. Researchers will also explore whether a milder pre-treatment regimen can be used before the cell infusion.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.